

# COVID-19 and Neurological Implications

**Gayatri Varikuti\***

Department of Biochemistry, GITAM Institute of Science, GITAM University, Visakhapatnam, India

\***Correspondence to:** Dr. Gayatri Varikuti, Department of Biochemistry, GITAM Institute of Science, GITAM University, Visakhapatnam, India, E-mail: [gayatri.varikuti@gmail.com](mailto:gayatri.varikuti@gmail.com)

**Citation:** Varikuti G (2020) COVID-19 and Neurological Implications. *Neurol Sci Neurosurg*, Volume 1:1. 103. DOI: <https://doi.org/10.47275/2692-093X-103>.

**Received:** February 24, 2020; **Accepted:** March 09, 2020; **Published:** March 14, 2020

## Short Commentary

COVID-19 causes severe respiratory failure due to brain infection. The latest COVID-19 revolution triggered by coronavirus SARS-CoV-2 owns plunged the world into turmoil with its wearily strong infection rate. Present SARS-CoV-2 disruption possesses grow pandemic, the experimental association running towards today to beat COVID-19 by interpreting molecular targets and discovering in the SARS-CoV-2 protein chain epitopes for the preparation of vaccines/antibodies. There are documented pieces of evidence that prove that patients also show neurological signs and symptoms, in addition to typical respiratory flu complaints. Present, the observation of a COVID-19 people showing trouble in breathing method regulated by the inspiratory region in the brainstem, is troubling [1]. Furthermore, neurological deficiencies reported from clinics from china, simple and problematic COVID-19 patients are sufficiently persuasive those neurological deficiencies could occur without being found in the recent outbreak [2].

Latest epidemic has now reached to nearly every nation and also developed pandemic, initial steps were started to understand COVID-19's syndromic severity. This year's SARS-CoV-2 which causes COVID-19 that affects the brain on different mechanisms. SARS-CoV-2 will also investigate frequent cases with odor failure, gait abnormality, speech changes, or abnormalities in eye movements and spasms for CNS activity [3]. Worldwide physicians particularly are having the first hand to research and communicate to the people impacted with COVID-19 present. Pharmacologic and clinical importance of cognitive early warning signs in COVID-19 patients can be determined by the fact that, in addition to separate columns for respiratory symptoms, the protocol designed to evaluate First Few X cases (FFX) and their close interactions with the World Health Organization provides with a special part for different neurological indications [4]. Pharmacologic and clinical importance of cognitive early warning signs in COVID-19 people will be determined by the evidence that in extension to different standards for respiratory indications, the rules intended to evaluate earlier some cases and those familiar interactions with the World Health Organization provides with a special part for different neurological indications. Consequently, records of COVID-19 affected persons reporting seizures in prominent places are troubling and have to be classified from fever symptoms predicted to arise in COVID-19 individuals in heavy-grade fever. Our previous happening with morphologically linked SARS-CoV clients also proven that bloodstream infections have

an impact on the cortex. It's recorded in past eruptions of SARS-CoV that it targets CNS also evidence that the brain is also an additional SARS-CoV4 target increases the risk of presenting higher peoples of neurological indications in present COVID-19 explosion [5]. SARS-CoV extracted from edema and neuronal degeneration brain tissue as seen in immunohistochemistry autopsies, in situ hybridization, and electron microscopic confirmation of neuronal viral infection[6]. The COVID-19 virus follows the same pattern as both viruses are taxonomically nearly similar. As the pandemic currently takes place, a comprehensive span of the syndromic neurological demonstration in COVID-19 will appear as higher investigation on more dangerous and simple and COVID-19 cases are released. While knowledge of the pathogenetic pathways influencing the CNS aggression would be established in over the period, however, is an essential requirement to differentiate across neurologically compromised COVID-19 individuals and some which do not show the CNS presence of signs and indications?

The hematogenic route tends to be the probable pathway for SARS-CoV-2 to enter the brain, but other routes to the CNS, such as through the ethmoid bone cribriform plate near the bulbous olfactory should be considered in early-stage COVID-19 infected patients with odor and taste loss followed by neurological signs and symptoms [7,8]. The latter aspect also tends to be significant from the perspective of choosing a course of therapy, as the treatment of COVID-19 cases with neurological interaction may need quite complex and intensive therapies similar to those without it. It cannot be exaggerated the importance of a detailed neurological examination of COVID-19 sufferers which can set rules a neurological deficiency of a person admitted after serological experiments proving the COVID-19 determination. The development of neurological defects accompanied by clinical experiments such as electrolytes, serum urea, blood gases, and creatinine can be beneficial in assessing the involvement of the CNS in victims harmed by COVID-19. Because neuronal destruction is not followed by significant inflammation in CoV-19 infections, clinical manifestations and indications of meningoencephalitis may not be relied on. Because we are in a training process about COVID-19 poses and how people vary from previously identified SARS-CoV affected cases, it is unlikely, if not difficult, to anticipate any specific clinical neurological examination to assess elevated-risk COVID-19 clients with secret CNS pathogens [9]. Given that neurological abnormalities exist in the disease that cannot be cured and will eventually lead to death patients with COVID-19, escaping from death in COVID-19



subjects may be an early stage of the investigation. A CSF biomarker or COVID-19 serum of patients with neurological defects would have been perfect for diagnosing COVID-19 cases of CNS association, but with these techniques not available till now. Spreading all relevant strategies for including or removing COVID-19 patients of neurological harm must be enforced.

## References

1. Li YC, Bai WZ, Hashikawa T (2020) The neuroinvasive potential of SARS-CoV2 may be at least partially responsible for the respiratory failure of COVID-19 patients. *J Med Virol* 92: 552-555. <https://doi.org/10.1002/jmv.25728>
2. Mao L, Wang M, Chen S, He Q, Chang J, et al. (2020) Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. *JAMA Neurol* 77:683-690. <https://doi.org/10.1001/jamaneurol.2020.1127>
3. Baig AM (2020) Neurological manifestations in COVID-19 caused by SARS-CoV-2. *CNS Neurosci Ther* 26:499-501. <https://doi.org/10.1111/cns.13372>
4. Xu J, Zhong S, Liu J, Li L, Li Y, et al. (2020) Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis. *Clin Infect Dis* 41: 1089-1096. <https://doi.org/10.1086/444461>
5. Li Y, Li H, Fan R, Wen B, Zhang J (2016) Coronavirus infections in the central nervous system and respiratory tract show distinct features in hospitalized children. *Intervirology* 59: 163-169. <https://doi.org/10.1159/000453066>
6. Van den Brand JM, Haagsma BL, van Riel D, Osterhaus AD, Kuiken T (2014) The pathology and pathogenesis of experimental severe acute respiratory syndrome and influenza in animal models. *J Compar Pathol* 151: 83-112. <https://doi.org/10.1016/j.jcpa.2014.01.004>
7. Khanna V, Khanna R, Hebbar S, Shashidhar V, Mundkar S, et al. (2011) Primary amoebic meningoencephalitis in an infant due to *Naegleria fowleri*. *Case Rep Neurol Med*. <https://doi.org/10.1155/2011/782539>
8. Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, et al. (2015) Severe neurologic syndrome associated with Middle East respiratory syndrome coronavirus (MERS-CoV). *Infection* 43: 495-501. <https://doi.org/10.1007/s15010-015-0720-y>
9. Conde G, Pájaro LD, Marzola ID, Villegas YR, Salazar LR (2020) Neurotropism of SARS-CoV 2: Mechanisms and manifestations. *J Neurol Sci* 412. <https://doi.org/10.1016/j.jns.2020.116824>